Cooperative Huntington's Observational Research Trial - Full Text View

Sponsors and Collaborators:	HP Therapeutics Foundation Huntington Study Group
Information provided by:	HP Therapeutics Foundation
ClinicalTrials.gov Identifier:	NCT00313495

Purpose

The purpose of this study is to collect prospective data from individuals who are part of a Huntington Disease (HD) family, in order to relate phenotypes between individuals and families with each other and genetic factors in order to learn more about HD, develop potential treatments for HD, and to plan for future research studies of experimental drugs aimed at slowing or postponing the onset and progression of HD.

Condition
Huntington Disease

Genetics Home Reference related topics: chorea-acanthocytosis familial encephalopathy with neuroserpin inclusion bodies familial paroxysmal nonkinesigenic dyskinesia Huntington disease McLeod neuroacanthocytosis syndrome

MedlinePlus related topics: Huntington's Disease Hurricanes

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	Cooperative Huntington's Observational Research Trial

Further study details as provided by HP Therapeutics Foundation:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Blood, DNA and Urine

Estimated Enrollment:	5000
Study Start Date:	February 2006
Estimated Study Completion Date:	December 2010
Estimated Primary Completion Date:	December 2010 (Final data collection date for primary outcome measure)

Detailed Description:

COHORT (Cooperative Huntington Observational Research Trial) is a coordinated research effort by Huntington Study Group research centers worldwide to prospectively collect data from consenting individuals who are affected by Huntington's disease (HD) and who are part of an HD family. The systematically accrued data from annual prospective assessments will relate clinical characteristics (phenotypes) between families with genetic and environmental factors. The knowledge from these relationships will better inform us about the onset and progression of HD, help identify potential interventions for HD, and aid in planning research studies of experimental treatments aimed at slowing or postponing the onset of HD. The consented collection of biological samples will further provide research material and correlative data for scientists to identify biomarkers that parallel the development and progression of HD. Identification of biomarkers will in turn contribute to our understanding of HD and enhance the efficiency and power of disease-modifying therapeutic trials.

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Those affected by Huntington's disease (HD)
Those who have tested positive for the HD gene
Parents, siblings, and children of an individual affected by HD or an individual who tested positive for the HD gene
Grandparents and grandchildren of anyone participating in COHORT who fulfills the requirements of (the above) category (1) or (2).
HD family members who have no risk for HD due to no family history (spouses) or negative gene testing. These individuals must have an affected or gene positive spouse or family member participating in COHORT to be included.
Those under 18 years of age may participate ONLY if they have HD

Criteria

Inclusion Criteria:

(1) Those affected by Huntington's disease (HD)
(2) Those who have tested positive for the HD gene
(3) Parents, siblings, and children of an individual affected by HD or an individual who tested positive for the HD gene
(4) Grandparents and grandchildren of anyone participating in COHORT who fulfills the requirements of (the above) category (1) or (2).
(5) HD family members who have no risk for HD due to no family history (spouses) or negative gene testing. These individuals must have an affected or gene positive spouse or family member participating in COHORT to be included.
(6) Those under 18 years of age may participate ONLY if they have HD

Exclusion Criteria:

(1) Anyone who does not fit the inclusion criteria

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00313495

Contacts

Contact: Huntington Study Group

800-487-7671

Show 43 Study Locations

Sponsors and Collaborators

HP Therapeutics Foundation

Huntington Study Group

Investigators

Principal Investigator:

Ira Shoulson, MD

University of Rochester/Huntington Study Group

More Information

The Huntington Study Group (HSG) is a non-profit group of physicians and other health care providers from medical centers in the U.S., Canada, Europe and Australia, experienced in the care of Huntington patients and dedicated to clinical research of HD. This link exits the ClinicalTrials.gov site

This link exits the ClinicalTrials.gov site

The Huntington Project brings together clinical and basic scientists, individuals and families affected by HD, advocacy groups, and others in the HD community to find and develop treatments that make a difference in the lives of those affected by HD. This link exits the ClinicalTrials.gov site

Responsible Party:	University of Rochester ( Ira Shoulson, MD/Principal Investigator )
Study ID Numbers:	COHORT
Study First Received:	April 10, 2006
Last Updated:	April 8, 2008
ClinicalTrials.gov Identifier:	NCT00313495
Health Authority:	United States: Institutional Review Board

Keywords provided by HP Therapeutics Foundation:

Huntington disease, observational, family members, biomarker

Study placed in the following topic categories:

Ganglion Cysts
Huntington disease
Basal Ganglia Diseases
Central Nervous System Diseases
Brain Diseases
Neurodegenerative Diseases
Dyskinesias
Cognition Disorders
Chorea

Delirium, Dementia, Amnestic, Cognitive Disorders
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Mental Disorders
Movement Disorders
Dementia
Huntington Disease
Delirium

Additional relevant MeSH terms:

Nervous System Diseases

ClinicalTrials.gov processed this record on January 16, 2009